Survey aims to discover how early diabetes diagnoses can aid better outcomes

A multinational survey of more than 10,000 people with type 2 diabetes has been launched by German family-owned drug major Boehringer Ingelheim and US drug major Eli Lilly (NYSE: LLY).

The survey has been developed in partnership with the International Diabetes Federation (IDF) to look at conversations between patients and more than 6,500 treating-physicians across 26 countries. The findings aim to provide in-depth insights into early conversations at diagnosis and when an additional therapy may be required beyond the first medication. The survey will also investigate how these early conversations may be linked to an individual’s wellbeing and other self-reported outcomes.

Anne Belton, vice president at the IDF, said: “Being diagnosed with type 2 diabetes can be a challenging and emotional period, which understandably, many people find overwhelming. The early conversations people with type 2 diabetes have with their physicians are essential. This new survey will provide valuable insights into these important early conversations and will help aid the development of solutions for physicians and people with type 2 diabetes. Together these will help deliver valuable support early on in the treatment pathway.”